Literature DB >> 3145268

Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa.

C A Gordon1, N A Hodges, C Marriott.   

Abstract

The interaction of five anti-pseudomonas antibiotics with both commercial and pseudomonas alginates was studied by investigation of their binding and diffusion characteristics. The two sources of alginate were qualitatively but not quantitatively similar in these respects. Unlike the beta-lactams, gentamicin and tobramycin bound avidly to both sources of alginate and, when the alginate gel to antibiotic ratio was high, the aminoglycosides exhibited diffusion coefficients which were approximately 20% of the beta-lactam values. At much lower ratios of alginate to antibiotic the aminoglycosides caused precipitation in the alginate with apparent disruption of the gel structure, and ultimately penetrated the gel at a faster rate than the beta-lactams. The strong aminoglycoside binding to alginate was reduced, but not eliminated by the presence of physiological concentrations of salts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145268     DOI: 10.1093/jac/22.5.667

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  52 in total

1.  Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life.

Authors:  Matthew R Parsek; Clay Fuqua
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

2.  Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate.

Authors:  N A Hodges; C A Gordon
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Use of slime dispersants to promote antibiotic penetration through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa.

Authors:  C A Gordon; N A Hodges; C Marriott
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

Authors:  Dominic Hill; Barbara Rose; Aniko Pajkos; Michael Robinson; Peter Bye; Scott Bell; Mark Elkins; Barbara Thompson; Colin Macleod; Shawn D Aaron; Colin Harbour
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics.

Authors:  J D Vrany; P S Stewart; P A Suci
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Swarm-cell differentiation in Salmonella enterica serovar typhimurium results in elevated resistance to multiple antibiotics.

Authors:  Wook Kim; Teresa Killam; Vandana Sood; Michael G Surette
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

7.  Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination.

Authors:  Warren E Rose; Daniel P Otto; Marique E Aucamp; Zach Miller; Melgardt M de Villiers
Journal:  Pharm Res       Date:  2014-06-17       Impact factor: 4.200

8.  Penetration of Candida biofilms by antifungal agents.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  YfiBNR mediates cyclic di-GMP dependent small colony variant formation and persistence in Pseudomonas aeruginosa.

Authors:  Jacob G Malone; Tina Jaeger; Christian Spangler; Daniel Ritz; Anne Spang; Cécile Arrieumerlou; Volkhard Kaever; Regine Landmann; Urs Jenal
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

Review 10.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.